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The transient receptor potential Ankyrin 1 (TRPA1) cation channel is activated by various pungent and irritant compounds, and it 
also mediates the perception of noxious cold. Identification of different agonists for this channel is important for understanding its 
activation mechanism. Therefore, a screen for novel TRPA1 agonists was performed using an agonist-induced calcium influx 
assay. Out of 90 compounds screened, pinacidil was identified as a novel agonist for this channel. Pinacidil is a known opener of 
the Katp channel, for which it has an EC50 value of 1–3 μmol/L. In comparison, the EC50 value of pinacidil for TRPA1 is relatively 
high (260 μmol/L). Recombinant HEK-TRPA1 cells did not respond to P1075, another Katp channel opener, suggesting that the 
effect of pinacidil on TRPA1 was highly specific. Further studies revealed that the agonist activity of pinacidil could be blocked 
by the TRP channel inhibitors, ruthenium red and HC-030031. Using glutathione (GSH) and site-specific mutagenesis, we 
demonstrated that pinacidil could activate TRPA1 by covalent modification of the critical amino acids C619, C639 and C663 in 
the N-terminus of TRPA1. 
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TRPA1 (ANKTM1, p120) belongs to the transient receptor 
potential (TRP) superfamily of cation channels and is pre-
sent in all species from yeast to mammals. It is critical for 
animal survival by influencing their ability to sense noxious 
environments, such as high or low temperatures [1], toxic 
chemicals [2] and strong mechanical stress [3]. Mammalian 
TRP channels, which are composed of six-transmembrane 
(6-TM) domains with a pore region between TM5 and TM6, 
can be divided into six subfamilies based on their sequ- 
ence homology. These subfamilies are: TRPC (canonical),  
TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), 
TRPML (mucolipin), and TRPA (ankyrin) [4–6]. TRPA1 is 
the only member of the TRPA sub-family, and it is distin-
guished from other TRP channels by the presence of 14 
repeated ankyrin domains within its N-terminus [7]. 
TRPA1 was originally identified in cultured human lung 
fibroblasts (IMR-90 cell line) [8]. Subsequent studies found 
that TRPA1 is highly expressed in dorsal root, trigeminal 
and nodose ganglion sensory neurons, and in cells of the 
inner ear [9,10]. Furthermore, some studies reported that the 
human TRPA1 protein is widely expressed outside of the 
CNS (e.g. intestine, lung, pancreas), and dysregulation of 
TRPA1 during oncogenic transformation has been postu-
lated [11,12]. Researchers have found that TRPA1 is sensi-
tive to cold temperatures of less than 17°C, and that it can 
be activated by a host of exogenous or endogenously-  
produced compounds including cinnamaldehyde [13,14], 
diallyl disulfide [15], 2-pentenal [16], hydroxyl fatty acid 
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[17], and morphanthridine analogue [18]. In addition, brady- 
kinin, a potent algogenic peptide released from sites of in-
jury and inflammation, can also activate TRPA1 via 
G-protein coupled bradykinin B2 receptors [13]. Studies on 
TRPA1 deficient mice supported the hypothesis that the 
channel plays a role in sensation of noxious cold, inflam-
matory pain and cough [16]. Therefore, TRPA1 is a prom-
ising target not only for the development of novel pain 
medications, but also for the development of potential new 
anti-tussive treatments for smoking-related diseases and 
environmental irritation [19]. 
TRP channels belong to the group of non-voltage gated, 
cation-permeable ion channels [20]. TRPA1 is a calci-
um-permeable, non-selective cation channel. Based on its 
channel characteristics, the activation of TRPA1 can be 
monitored by calcium assay and electrophysiology. In this 
study, we established an integrated assay system that used a 
Fluo3-based calcium influx assay together with whole cell 
patch-clamp analysis to identify novel TRPA1 channel ago-
nists. Using this system, we demonstrated that pinacidil 
could activate recombinant human TRPA1 channels in 
HEK293 cells. 
1  Materials and methods 
1.1  Reagents   
The HDB WASH Free Calcium Assay Kit was supplied by 
HD Biosciences (Shanghai, China). The culture medium, 
pcDNA3.1-hygro(+) vector, hygromycin B and Lipofecta- 
mine 2000 were purchased from Invitrogen (USA). Cinna- 
maldehyde, trans-2-pentenal, tetraethylthiuram disulfide, 
ruthenium red, pinacidil and P1075 were purchased from 
Sigma (USA). 
1.2  Cloning and expression of human TRPA1  
The human TRPA1 cDNA in the pCMV6-XL4 vector was 
purchased from ORIGENE (USA), and the sequence was 
verified by restriction mapping and DNA sequencing. The 
pCMV6-XL4-TRPA1 plasmid was digested with the re-
striction enzyme Not I to isolate the human TRPA1 fragment. 
The obtained fragment was inserted into the mammalian ex-
pression vector, pcDNA3.1-hygro(+), at the Not I site to gen-
erate the pcDNA3.1-hygro(+)-TRPA1 recombinant plasmid. 
The pcDNA3.1-hygro(+)-TRPA1 plasmid was then trans-
fected into HEK293 cells using Lipofectamine 2000. Stable 
HEK293 cells expressing full length human TRPA1 were 
selected in the presence of 1 mg/mL hygromycin B and cul-
tured in a humidified atmosphere of 5% CO2 at 37°C in Dul-
becco’s Modified Eagle Medium supplemented with 10% 
fetal bovine serum and 2 mmol/L L-glutamine. 
A series of cysteine to serine TRPA1 mutants at C619, 
C639 and C663 were created using the Stratagene (USA) 
site-directed mutagenesis kit according to manufacturer’s 
instructions. Mutations were confirmed by DNA sequencing. 
The mutant and wild-type TRPA1 constructs were then 
transiently transfected into HEK293 cells for functional 
detection by calcium influx assay. 
1.3  Calcium influx assay 
A HDB WASH Free Calcium Assay Kit (HD Biosciences, 
Shanghai, China) was used to measure intracellular calcium 
concentration on a FlexStation 384II plate reader according 
to the manufacturer’s instructions. Cells were seeded at a 
density of 4104 cells/well in a Matrigel-coated, 96-well 
black plate and incubated in a CO2 incubator overnight be-
fore running the assay. The growth medium was replaced 
next day with calcium assay buffer containing 4 μmol/L 
Fluo-3/AM, 1 mmol/L probenecid and 0.4 g/L pluronic 
F127. The assay was performed by incubating the plate at 
37°C for 1 h on the FlexStation plate reader, with an excita-
tion wavelength of 485 nm and an emission wavelength of 
525 nm. In the antagonist test experiment, following prein-
cubation of the antagonist on the cells for 10 min, agonist 
was applied to elicit a residual fluorescence signal that was 
recorded on the FlexStation plate reader. 
1.4  Electrophysiology 
HEK293-TRPA1 cells were transferred to a continuous-
ly-perfused recording chamber mounted on the stage of an 
inverted microscope. For whole-cell patch clamp experi-
ments, the standard bath solution consisted of: 140 mmol/L 
NaCl, 5 mmol/L KCl, 2 mmol/L CaCl2, 1 mmol/L MgCl2, 
10 mmol/L HEPES, 10 mmol/L D-glucose, pH 7.4 (NaOH). 
The pipette solution for whole-cell experiments contained 
140 mmol/L KCl, 1 mmol/L CaCl2, 1 mmol/L MgCl2, 10 
mmol/L EGTA, 10 mmol/L HEPES, 10 mmol/L D-glucose, 
pH 7.3 (KOH). All experiments were performed at room 
temperature using a HEKA EPC-10 amplifier (HEKA Elec-
tronics, Lambrecht/Pfalz, Germany). Patch pipettes of 3–5 
megaohms were fabricated from borosilicate glass capillar-
ies. Whole cell access was obtained by using negative pres-
sure to rupture the cell membrane, and series resistance 
compensated for optimal voltage control of the cell mem-
brane. A holding potential of 60 mV was applied from an 
HEKA EPC-10 amplifier controlled by Patchmaster™ 
software. Experiments were carried out and analyzed under 
the control of the Patchmaster™ software (HEKA Elec-
tronics). Whole-cell currents were filtered at 3 kHz (four- 
pole Bessel filter) and sampled continuously at 5 kHz. 
1.5  Glutathione adduct reaction 
Electrospray ionization mass spectrometry (ESI-MS) was 
used to determine that reaction of TRPA1 agonists and glu-
tathione in water at room temperature produced glutathione 
adducts. 
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1.6  Data analysis 
Calcium assay data were recorded as RFU values (relative 
fluorescence units) using SoftMax Pro 4.8 software. The 
concentration dose responses were analyzed using Graph- 
Pad Prism 4 software. Data are reported as mean ± SEM (n 
indicates the number of experiments). Student’s t-test was 
used for all statistical calculations. 
2  Results 
2.1  Primary screen of TRPA1 agonists by calcium  
influx assay 
Based on the calcium-permeable property of the TRPA1 
channels, a high-throughput screen based on calcium influx 
in response to TRPA1 activation was established. The assay 
was optimized for cell density, loading time and DMSO 
tolerance. Cinnamaldehyde (CA), trans-2-pentenal (2-TP) 
and tetraethylthiuram disulfide (TED), which are known 
agonists of TPRA1, were used to test the assay system. As 
expected, all three compounds induced a large and sustained 
increase in fluorescence in TRPA1 cells, while generating 
no response in the non-transfected HEK293 cells (data not 
shown). Around 90 compounds were tested by this screen-
ing system, and four hits, including pinacidil, were identi-
fied as potential agonists of TRPA1 (Figure 1(a)). Compa-
rable calcium increases were observed with 200 μmol/L 
pinacidil, while no response to pinacidil, even at high con-
centration, was observed in non-transfected HEK293 cells  
 
 
Figure 1  Activation of the TRPA1 channel by pinacidil in recombinant HEK293 cells. (a) Primary screen of 90 compounds assayed by the change in Rela-
tive Fluorescence Units (RFU). Four hits were identified by the screen. (b) Pinacidil induced Ca2+ influx in a dose-dependent manner in HEK293-hsTRPA1 
cells, while it failed to evoke Ca2+ influx in non-recombinant HEK293 host cells. (c) Chemical structures of cinnamaldehyde and pinacidil. (d) P1075 does 
not activate TRPA1. (e) The TRP channel antagonists, ruthenium red and HC-030031, inhibit the calcium response induced by pinacidil in TRPA1 cells. The 
curve is plotted as the change in RFU in response to 300 μmol/L pinacidil for 10 min after the addition of antagonist. RFU were calculated by normalizing 
each data point to the maximal response. Data points represent means ± SEM (n = 4–5). 
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(Figure 1(b)). EC50 values for the known TRPA1 agonists 
cinnamaldehyde, trans-2-pentenal, tetraethylthiuram disul-
fide were also measured using the calcium influx assay (Ta-
ble 1), and the data obtained were similar to other published 
data. 
Pinacidil is an ATP-dependent K+ channel activator (its 
structure is shown in Figure 1(c)). The application of pina-
cidil on human coronary artery vascular smooth muscle 
cells can cause an outward current [21]. Although it has 
been reported that HEK293 cells do not express any en-
dogenous ATP-dependent K+ channels [22–24], to rule out 
the possibility that pinacidil-induced TRPA1 activation was 
not caused by activation of Katp channels, another Katp 
opener, P1075 [25], with a similar structure to pinacidil, 
was tested in the calcium influx assay. As shown in Figure 
1(d), P1075 had no effect on TRPA1 activation. 
The nonselective TRP channel antagonist, ruthenium red, 
and the TRPA1-specific antagonist, HC-030031, were used 
to test if they could block pinacidil-induced calcium influx 
in HEK293-TRPA1 cells. The results demonstrated a con-
centration-dependent inhibition with IC50 values ranging 
from 80–800 nmol/L for ruthenium red (RR) and 5–25 
μmol/L for HC-030031 (HC) (Figure 1(e)). 
2.2  Confirmation of TRPA1 agonists by  
electrophysiology 
In electrophysiological studies, the characteristic inward 
current and desensitation with repeated stimulation was 
observed when applying cinnamaldehyde (1 mmol/L) to 
TRPA1-expressing cells (data not shown). These cinnamal-
dehyde-induced currents were inhibited by the universal 
antagonist, RR, and the TRPA1-specicific antagonist, 
HC-030031 (Figure S1(A,B)). This system was further ap-
plied to confirm the activation effect of pinacidil on TRPA1. 
We found that large membrane currents were elicited by 
pinacidil (1 mmol/L) at 60 mV in HEK293 cells that ex-
pressed human TRPA1 (Figure S1(E)) but not in non- 
transfected HEK293 cells (data not shown). Moreover, the-
se agonist-induced current responses were inhibited by RR 
(30 μmol/L) and HC-030031 (50 μmol/L) (Figure S1(C,D)). 
2.3  Selectivity study 
To test whether pinacidil acts specifically on TRPA1, the 
effect of pinacidil on two related cation channels, human 
TRPV3 and TRPM8, was tested. Pinacidil exerted no effect 
on HEK293-hsTRPV3 cells and evoked a very weak fluo-
rescence increase in HEK293-hsTRPM8 cells at high con-
centration (100–1000 μmol/L) (Figure 2(a),(b)). Consider-
ing these data together with our other results, we therefore 
suggest that pinacidil acts as a specific agonist for TRPA1. 
2.4  ER calcium stores are not responsible for  
pinacidil-induced calcium release 
The increased calcium levels detected in the HEK293- 
TRPA1 cells by the calcium influx assay may be due to 
release from intracellular Ca2+ stores (the endoplasmic re-
ticulum) or influx from the extracellular solution. The cal-
cium contained in the ER can be depleted by blocking 
ATP-dependent Ca2+ uptake with thapsigargin. To deter-
mine the source of the pinacidil induced calcium, the TRPA1 
cells were pre-incubated with or without thapsigargin (10 
mol/L) and then stimulated with TRPA1 agonists. No sig-
nificant difference was observed following stimulation with 
cinnamaldehyde (30 mol/L) or pinacidil (300 mol/L) (Fig-
ure 2(c)). These observations suggested that the calcium sig-
nal increase mainly resulted from the opening of cell mem-
brane TRPA1 channels, rather than release from the ER. 
2.5  In vitro glutathione adduct formation 
Covalent modification of cysteines in TRPA1 is regarded as 
an important activation mechanism mediated by most 
TRPA1 agonists. A glutathione (GSH) adduction test was 
performed to confirm the covalent modification of cysteine 
residues by TRPA1 agonists in vitro. To investigate the ac-
tivation mechanism of the TRPA1 agonists, GSH was com-
bined with cinnamaldehyde, pinacidil or P1075 and allowed 
to react at room temperature. The samples were then meas-
ured by electrospray ionization mass spectrometry 
(ESI-MS). GSH alone existed as both a monomer and a 
dimer in solution, MH+, m/z (307, 613) (Figure S2(A)). 
When reacted with cinnamaldehyde and pinacidil, glutathi-
one adducts of the predicted mass were detected by ESI-MS 
(Figures 3(a), S2(B)). However, no adducts were observed 
from the reaction of P1075 and GSH sample (data not 
shown). These data suggest that pinacidil can covalently 
modify cysteine residues in TRPA1. 
Table 1  Summary of the activity of TRPA1 agonists in HEK293-hsTRPA1 cellsa) 
Agonist Cinnamaldehyde Trans-2-pentenal Tetraethylthiuram Pinacidil 
EC50 (mol/L) 12.96±2 25.57±3.4 0.10±0.1 260±18 
HILLSLOPE 2.393 2.147 1.308 3.21 
Maximum response (%) 113.3±6.1 125.9±9.3 153±17 119.5±6 
RR IC50 (mol/L)   0.83±0.07   0.75±0.05  0.23±0.04 0.08±0.01 
HC-030031 IC50 (mol/L) 21.94±7.5 18.75±5.6 6.26±2.8 6.6±2.3 
a) Maximum response is the ratio of the high response relative to the response of HEK293-hsTRPA1 cells to 40 μmol/L cinnamaldehyde. Values are the 
mean and standard deviations for n= 4–5 concentration-response experiments. 
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Figure 2  Selectivity of pinacidil on different HEK293-hsTRP cell lines, 
and the effect of thapsigargin on the HEK-TRPA1 cell line. (a) Dose- 
dependent changes on calcium influx induced by DPBA (TRPV3 agonist) 
and pinacidil in HEK293-hsTRPV3 cells. (b) Dose-dependent calcium 
influx responses induced by Menthol (TRPM8 agonist) and pinacidil in 
HEK293-hsTRPM8 cells. The y-axis represents the fluorescence change 
mediated by Fluo-3 in RFU. (c) Induction of calcium responses in HEK293- 
hsTRPA1 cells induced by the test compounds with or without 10 μmol/L 
thapsigargin pre-incubation. Data points represent means ± SEM (n = 4–5). 
2.6  Competitive inhibition of TRPA1 agonists by GSH  
To further verify the activation mechanism, cinnamalde-
hyde (1 mmol/L) or pinacidil (1 mmol/L) were reacted with 
different concentrations of GSH and applied to TRPA1 cells. 
A significant reduction in calcium influx was observed with 
the addition of higher concentrations of GSH (Figures 3(b), 
S2(C)). Together with the in vitro glutathione adduct for-
mation data, it is clear that TRPA1 and GSH are both capa-
ble of reaction with pinacidil. 
2.7  Three cysteine residues on TRPA1 are critical for 
pinacidil activation 
Covalent modification of cysteine residues in the N-   
terminus of TRPA1 is thought to underlie the agonist activ-
ity of chemically reactive compounds such as cinnamalde-
hyde. Furthermore, three cysteine residues (C619, C639 and 
C663) were identified as the specific requirement site for 
agonists that activate the TRPA1 channel by covalent modi-
fication [26]. To determine whether a similar mechanism 
underlies the activity of the novel TRPA1 agonist, pinacidil, 
a series of single point-mutations and multiple point-   
mutations in TRPA1 were generated. We studied the effects 
of cinnamaldehyde and pinacidil on calcium fluorescence in 
HEK293 cells transiently transfected with WT TRPA1 or 
cysteine mutants of TRPA1 (Figures 4(b), S2(D)). As illus-
trated in Figure 4(b), single point-mutations of C619 or 
C639, and double point-mutation of C639/663, significantly 
changed the pinacidil-induced Ca2+ influx compared to 
wide-type TRPA1. The observation that double point muta-
tion of C639/663S resulted in a greater reduction of Ca2+ 
influx compared to the C639 single point mutation suggest-
ed that C663 also contributes to the sensitivity of TRPA1 to 
pinacidil. All of these results indicated that the three cyste-
ine residues in theintracellular N-terminus of TRPA1 confer 
sensitivity to pinacidil. 
3  Discussion  
In this study, we established an integrated assay system to 
screen and verify TRPA1 agonists. This system included a 
calcium influx assay and patch-clamp whole cell electro-
physiology. Through this approach, the previously reported 
Katp channel opener, pinacidil, was identified as a novel 
agonist for TRPA1. 
TRPA1 is a non-selective cation channel that is permea-
ble to calcium, and its activation leads to an elevation of 
intracellular calcium. Therefore, TRPA1-mediated intracel-
lular calcium influx can be monitored by the use of the flu-
orescent calcium indicator, Fluo-3. Because cinnamalde-
hyde, tetraethylthiuram disulfide and trans-2-pentenal have 
been reported as agonists of the TRPA1, we used these 
compounds to characterize and validate our TRPA1 screen-
ing system. The known agonist activity of cinnamaldehyde 
was observed by calcium influx in TRPA1-expressing cells, 
but not in wild-type cells, indicating that the calcium influx 
was mediated by TRPA1 activation. Also, our dose res- 
ponse curve data and EC50 values for the agonists were con-
sistent with those reported in the literature [9,13,27]. The 
TRP channel antagonists, ruthenium red and HC-030031, 
have been used to test the specificity of potential TRPA1 
agonists. Ruthenium red is a universal antagonist for the 
TRP channels, and it displayed a potent, membrane-    
impermeable antagonism effect on TRPA1 currents. HC- 
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Figure 3  GSH forms adducts with pinacidil and competitively inhibits TRPA1 agonists applied to HEK293-hsTRPA1 cells. (a) Pinacidil and glutathione 
were mixed in water at room temperature to produce glutathione adducts. Adduct formation was determined by electrospray ionization mass spectrometry 
(ESI-MS). (b) Calcium responses induced by pinacidil in HEK293-hsTRPA1 cells in the presence of 50 or 15 mmol/L GSH. *P <0.05, **P <0.01 versus 
pinacidil group. 
030031, a newly-reported, selective antagonist of TRPA1 
channels [28,29], showed an effect similar to that of ruthe-
nium red. The antagonist effects of ruthenium red and 
HC-030031 against TRPA1 agonists were confirmed in our 
assays, with IC50 values similar published data being ob-
served [10,28]. Together, these data validated our assay sys-
tem for the screening of TRPA1 agonists. For the screening 
assay, a series of compounds was tested on the HEK293 
TRPA1-expressing cells. To identify false positives and ex-
clude non-specific compounds, the hits were screened in a 
secondary assay using cells not expressing recombinant 
TRPA1. As a result, pinacidil was identified as able to evoke 
a calcium response that could be blocked by the TRPA1 
blockers, ruthenium red and HC-030031. All of these data 
suggest that pinacidil is an agonist of the TRPA1 channel. 
Moreover, in contrast to TRPA1, pinacidil did not stimulate 
calcium influx via TRPV3 and TRPM8. These results suggest 
that pinacidil may be a specific agonist of TRPA1, rather than 
a general agonist of TRP family channels. 
To investigate ion channel function, electrophysiological 
measurements, in particular patch clamp, have long been 
considered as the “Gold Standard”. To confirm the TRPA1 
agonistic activity of pinacidil by a relatively direct approach, 
we used the whole-cell patch clamp technique. It has been 
reported that TRPA1 is often desensitized in the presence of 
extracellular Ca2+ [10,30]. It has even been reported that 
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Figure 4  Three cysteine residues in the intracellular N-terminus of 
TRPA1 confer sensitivity to pinacidil. (a) Structure of one TRPA1 subunit; 
the dark dots downstream of the ankyrin repeats represent the target Cys-
teine C663, C639 and C619 (Adapted from Michael J. Caterina, 2007). (b) 
Calcium influx mediated by WT and cysteine mutant TRPA1 in response 
to 300 μmol/L pinacidil. *P <0.05, **P <0.01 versus wtTRPA1 group. 
calcium ions alone can directly gate heterologously ex-
pressed TRPA1 [31,32]. Therefore, many researchers 
choose to use a calcium-free solution in the patch clamp 
experiment to avoid desensitization. However, some re-
ported TRPA1 agonists such as icilin, which uses a different 
activation mechanism to other TRPA1 agonists, display a 
requirement for calcium ions to elicit an agonist response 
[31,33]. Calcium ions were shown to potentiate the ago-
nist-mediated activation of TRPA1 without changing the 
property of the agonists. To avoid the misjudgment of 
compound activity, we chose to use a solution containing 
calcium ions in our electrophysiology experiments. Under 
these conditions, pinacidil and cinnamaldehyde evoked a 
slowly developing current, and desensitization was ob-
served with repeated stimulation. These currents were im-
peded by the TRP channel non-specific antagonist, ruthe-
nium red, and the TRPA1-specific antagonist, HC-030031. 
All of the results showed remarkable consistency with pre-
viously reported TRPA1 channel properties, and strongly 
suggested that pinacidil is a novel agonist for TRPA1. 
Although TRPA1 can be activated by various stimuli in-
cluding noxious cold, irritant substances, activation of some 
PLC-related GPCRs, and even mechanical stimulation, the 
best characterized activation mechanism is via covalent 
modification of intracellular cysteines [34]. The in vitro 
formation of adducts between GSH and TRPA1 agonists 
reported by Macpherson was investigated to determine the 
mechanism of action of pinacidil. Pinacidil weakly formed 
adducts with the cysteine-containing tripeptide glutathione 
(Glu-Cys-Gly) compared to cinnamaldehyde, while P1075 
did not form adducts with GSH. When pinacidil was applied 
to TRPA1-expressing cells together with different concen-
trations of GSH, a significant reduction in the calcium sig-
nal was observed at higher concentrations of GSH. GSH has 
been shown to be a competitive inhibitor of TRPA1 ago-
nists. Our results also suggested that pinacidil activated 
TRPA1 by covalent modification of intracellular cysteines. 
Comparing the structure of pinacidil and P1075, a conju-
gated system of double and triple bonds is observed in pina-
cidil, while this conjugation is broken by one more single 
bond in P1075. This structural difference may explain the 
different reactivity of TRPA1 with pinacidil and P1075. 
Pinacidil is an ATP-sensitive K channel opener and has 
been approved for the clinical treatment of mild to moderate 
hypertension [35]. Here, we present for the first time its 
off-target activity on TRPA1. A recent review summarized 
that a number of marketed drugs have been reported to ac-
tivate the TRPA1 channel in additional to their intended 
targets, suggesting that their side effects may be partially 
explained by interaction of these drugs with TRP channels 
[14]. Headache is the main side effect of pinacidil treatment 
in antihypertension [36]. Over the past decade, several 
studies have revealed that members of the TRP ion channel 
family, including TRPA1, are fundamental molecules for 
the sensation of pain [37,38]. Our data suggest that activa-
tion of the TRPA1 receptor by pinacidil is a possible expla-
nation for this drug-induced headache side effect. Therefore, 
structural modification of these compounds to remove their 
activity at TRPA1 may alleviate their side effects of pain. 
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Figure S1  Electrophysiology data proved that pinacidil activates TRPA1. 
Figure S2  GSH adducts and GSH competitively reacted with agonists on HEK293-hsTRPA1 cells. 
The supporting information is available online at csb.scichina.com and www.springerlink.com. The supporting materials 
are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains en-
tirely with the authors.
